{"Title": ["First Week of FATE February 2021 Options Trading", "If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now", "DNLI Halts DNL747 Development, IMRN Skyrockets, XENT's Sinus Implant Gets New C-Code", "Here's Why Fate Therapeutics Rose 18.4% in May", "Notable Tuesday Option Activity: FATE, NWL, ALNY", "Here's Why Fate Therapeutics Stock Jumped Higher Today", "BUZZ-U.S. STOCKS ON THE MOVE-Vroom, Amazon, Applied DNA", "BUZZ-U.S. STOCKS ON THE MOVE-Fate Therapeutics, Tiffany, MoneyGram", "First Week of FATE February 2021 Options Trading", "Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock", "Fate Therapeutics Inc (FATE) Q1 2020 Earnings Call Transcript", "3 Monster Growth Stocks With Still Plenty of Gas in the Tank", "Is Fate Therapeutics a Buy?", "Why Fate Therapeutics Tumbled 23.9% in March", "2 Top U.S. Stocks to Watch in April", "My Top Biotech Stocks to Buy in the Market Crash", "2 Top Gene Editing Stocks to Watch in June", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Apple, Tyson Foods, Under Armour", "Here's Why Fate Therapeutics Rose as Much as 18.7% Today", "Health Care Sector Update for 04/03/2020: ECOR, FATE, IMAB, JNJ, PFE, MRK, ABT, AMGN", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Twitter, GE, Riot Blockchain", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Twitter, Riot Blockchain, Apple", "Fate Therapeutics Seals Deal With JNJ For Cancer Immunotherapies, Stock Jumps", "Fate Therapeutics Shares Cross Below 200 DMA", "Fate Therapeutics Snags $3 Billion-Plus Deal With Johnson & Johnson", "Fate Therapeutics Inc (FATE) Q4 2019 Earnings Call Transcript", "2 Top Biotech Stocks to Buy Right Now", "3 Top Drug Stocks to Own In 2020", "Top Gainers: THOR Acquired, FTSV Up On Magrolimab Data, Investors Believe FATE", "Fate Therapeutics Soars as Much as 45.8% After Giving Investors What They Wanted", "2 Top Biotech Stocks to Buy in December", "Here's Why Fate Therapeutics Dropped as Much as 19.9% Today", "Here's My Top Stock to Buy in March", "FATE Crosses Below Key Moving Average Level", "Fate Therapeutics, Inc. (FATE) Q2 2019 Earnings Call Transcript", "First Week of September 20th Options Trading For Fate Therapeutics (FATE)", "Are Natural Killer Cells the Next Big Thing in Immunotherapy?", "Thursday's ETF Movers: XLE, XBI", "Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript", "Earnings Reaction History: FATE THERAPEUTC, 60.0% Follow-Through Indicator, 6.0% Sensitive", "Fate Therapeutics Inc (FATE) Q3 2019 Earnings Call Transcript", "FATE Crosses Below Key Moving Average Level", "Fate Therapeutics, Inc. (FATE) Q2 2019 Earnings Call Transcript", "First Week of September 20th Options Trading For Fate Therapeutics (FATE)", "Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates", "Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy", "3 Small Biotech Stocks at 52-Week Highs -- Are They Buys?", "Health Care Sector Update for 09/18/2018: FATE, MOR, CI, NAVB", "After-Hours Earnings Report for March 5, 2019 : ROST, COO, URBN, AVAV, AMBA, SSW, FATE, REGI, AGS, UNFI, PARR, VSLR", "Diamond Stocks Aren't Forever -- Your Shot At An Easy 35.8% Gain", "After-Hours Earnings Report for March 5, 2018 : YY, DSGX, ALOG, PARR, FRPT, FATE, NVGS, NX, PKOH, ASNA, ADUS, NLS", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Here's Why Fate Therapeutics Rose as Much as 18% Today", "Tuesday Sector Leaders: Gas Utilities, Biotechnology Stocks", "3 Stocks Under $10 That Surged Today", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Tuesday's ETF Movers: GXC, XBI", "Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?", "After-Hours Earnings Report for August 14, 2017 : SBS, HOLI, EXTR, ATTO, FSM, PLAB, HIL, AST, OCX, FATE, WPRT, SITO", "Health Care Sector Update for 08/08/2017: FATE,FGEN,BIOA", "After-Hours Earnings Report for May 15, 2017 : VIPS, ABY, EDIT, DXPE, FSM, VRAY, GAIN, KURA, FATE, VOXX, CRME, AMRS", "Surging Earnings Estimates Signal Good News for Fate Therapeutics (FATE)", "Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro", "Explosive Stocks Under $10", "Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%", "Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?", "After-Hours Earnings Report for August 14, 2017 : SBS, HOLI, EXTR, ATTO, FSM, PLAB, HIL, AST, OCX, FATE, WPRT, SITO", "Wednesday Sector Laggards: Biotechnology, Drugs", "Can The Uptrend Continue for Fate Therapeutics (FATE)?", "Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher", "Health Care Sector Update for 08/08/2016: FATE,MEIP,CHEK", "Fate Therapeutics (FATE) Shares March Higher, Can It Continue?", "Geron (GERN) Q2 Earnings: What's in Store for the Stock?", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%", "Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up", "Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%", "Midday Update: Wall Street Rallies as New Poll Dims Chances of Brexit", "Close Update: Wall Street's Relief Rally Triggered by Fading Brexit Support", "Health Care Sector Update for 06/20/2016: FATE,LPTN,EGRX", "Arena (ARNA) Q2 Earnings: What's in Store for the Stock?", "Geron (GERN) Q2 Earnings: What's in Store for the Stock?", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%", "Vertex (VRTX) Down on CRL for Kalydeco Label Expansion", "Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues", "Wednesday Sector Laggards: Biotechnology, Drugs", "Exelixis's Cabozantinib Granted Priority Review in the U.S.", "Fate (FATE) to Move ProTmune into Phase I/II Study in Mid-16", "Health Care Sector Update for 05/17/2016: FATE, ABEO", "Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 8.3%", "Fate Therapeutics (FATE) Catches Eye: Stock Moves 5.3% Higher", "Health Care Sector Update for 10/06/2015: CPRX, INFI, FATE", "Fate Therapeutics (FATE) in Focus: Stock Rises 6.6% - Tale of the Tape", "Juno Therapeutics (JUNO) Q1 Loss Narrower than Expected - Analyst Blog", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 46% - Tale of the Tape", "Adaptimmune Therapeutics (ADAP) in Focus: Stock Tanks 10.5%", "Fate Therapeutics (FATE) Jumps: Stock Moves 12.4% Higher - Tale of the Tape", "Will Fate Therapeutics (FATE) Continue to Surge Higher? - Tale of the Tape", "Fate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session - Tale of the Tape", "After-Hours Earnings Report for November 11, 2014 : FOSL, YY, TAHO, HMIN, LXFT, STKL, AERI, MGNX, SUPN, PFIE, FATE, CLSN", "Fate Reports In-Line Loss in Q4 - Analyst Blog", "Fate Therapeutics' Prohema in Phase II Study - Analyst Blog", "Fate Therapeutics (FATE) Shares March Higher, Can It Continue? - Tale of the Tape", "Fate Therapeutics prices IPO at $6, at low end of the revised range", "Orphan disease biotech Fate Therapeutics decreases range and increases shares offered", "9 US IPOs planned for the week of Sep 30", "13 US IPOs planned for the week of Sep 23", "12 US IPOs planned for the week of Sep 16", "Orphan disease biotech Fate Therapeutics sets terms for $60 million IPO", "Insiders Buy Shares at Fate Therapeutics and ChemoCentryx"], "Elapsed Time": ["JUN 19, 2020", "JUN 13, 2020", "JUN 10, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 19, 2020", "MAY 15, 2020", "MAY 12, 2020", "APR 30, 2020", "APR 29, 2020", "APR 9, 2020", "APR 8, 2020", "APR 7, 2020", "MAY 16, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 2, 2020", "MAR 13, 2020", "APR 3, 2020", "MAR 3, 2020", "JAN 23, 2020", "JAN 3, 2020", "DEC 9, 2019", "DEC 9, 2019", "DEC 9, 2019", "NOV 6, 2019", "MAR 6, 2020", "SEP 17, 2019", "AUG 7, 2019", "JUL 26, 2019", "JUL 8, 2019", "JUN 6, 2019", "MAR 6, 2019", "MAR 5, 2019", "NOV 5, 2019", "SEP 17, 2019", "AUG 7, 2019", "JUL 26, 2019", "NOV 1, 2018", "OCT 8, 2018", "OCT 3, 2018", "SEP 18, 2018", "MAR 5, 2019", "APR 19, 2018", "MAR 5, 2018", "FEB 24, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 18, 2018", "DEC 30, 2017", "JUL 24, 2018", "DEC 5, 2017", "AUG 14, 2017", "AUG 8, 2017", "MAY 15, 2017", "MAR 28, 2017", "MAR 8, 2017", "MAR 7, 2017", "DEC 28, 2017", "DEC 5, 2017", "AUG 14, 2017", "OCT 12, 2016", "SEP 23, 2016", "AUG 9, 2016", "AUG 8, 2016", "FEB 22, 2017", "AUG 1, 2016", "JUL 29, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 20, 2016", "JUN 20, 2016", "JUN 20, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "FEB 8, 2016", "FEB 4, 2016", "FEB 3, 2016", "JAN 29, 2016", "JAN 27, 2016", "MAY 17, 2016", "APR 11, 2016", "FEB 29, 2016", "NOV 18, 2015", "OCT 6, 2015", "JUL 1, 2015", "MAY 12, 2015", "MAY 7, 2015", "JAN 12, 2016", "APR 21, 2015", "JAN 5, 2015", "NOV 19, 2014", "NOV 11, 2014", "MAR 20, 2014", "MAR 13, 2014", "MAY 7, 2015", "OCT 1, 2013", "SEP 30, 2013", "SEP 30, 2013", "SEP 23, 2013", "SEP 16, 2013", "SEP 3, 2013", "OCT 8, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/first-week-of-fate-february-2021-options-trading-2020-06-19", "https://www.nasdaq.com/articles/if-you-invested-%241000-in-fate-therapeutics-ipo-this-is-how-much-money-youd-have-now-2020", "https://www.nasdaq.com/articles/dnli-halts-dnl747-development-imrn-skyrockets-xents-sinus-implant-gets-new-c-code-2020-06", "https://www.nasdaq.com/articles/heres-why-fate-therapeutics-rose-18.4-in-may-2020-06-09", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-fate-nwl-alny-2020-06-09", "https://www.nasdaq.com/articles/heres-why-fate-therapeutics-stock-jumped-higher-today-2020-06-09", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-vroom-amazon-applied-dna-2020-06-09", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-fate-therapeutics-tiffany-moneygram-2020-06-09", "https://www.nasdaq.com/articles/first-week-of-fate-february-2021-options-trading-2020-06-19", "https://www.nasdaq.com/articles/heres-why-big-buyers-are-excited-about-this-cancer-immunotherapy-stock-2020-05-15", "https://www.nasdaq.com/articles/fate-therapeutics-inc-fate-q1-2020-earnings-call-transcript-2020-05-12", "https://www.nasdaq.com/articles/3-monster-growth-stocks-with-still-plenty-of-gas-in-the-tank-2020-04-30", "https://www.nasdaq.com/articles/is-fate-therapeutics-a-buy-2020-04-29", "https://www.nasdaq.com/articles/why-fate-therapeutics-tumbled-23.9-in-march-2020-04-09", "https://www.nasdaq.com/articles/2-top-u.s.-stocks-to-watch-in-april-2020-04-08", "https://www.nasdaq.com/articles/my-top-biotech-stocks-to-buy-in-the-market-crash-2020-04-07", "https://www.nasdaq.com/articles/2-top-gene-editing-stocks-to-watch-in-june-2020-05-16", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-apple-tyson-foods-under-armour-2020-04-03", "https://www.nasdaq.com/articles/heres-why-fate-therapeutics-rose-as-much-as-18.7-today-2020-04-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-03-2020%3A-ecor-fate-imab-jnj-pfe-mrk-abt-amgn-2020-04-03", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-twitter-ge-riot-blockchain-2020-04-03", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-twitter-riot-blockchain-apple-2020-04-03", "https://www.nasdaq.com/articles/fate-therapeutics-seals-deal-with-jnj-for-cancer-immunotherapies-stock-jumps-2020-04-02", "https://www.nasdaq.com/articles/fate-therapeutics-shares-cross-below-200-dma-2020-03-13", "https://www.nasdaq.com/articles/fate-therapeutics-snags-%243-billion-plus-deal-with-johnson-johnson-2020-04-03", "https://www.nasdaq.com/articles/fate-therapeutics-inc-fate-q4-2019-earnings-call-transcript-2020-03-03", "https://www.nasdaq.com/articles/2-top-biotech-stocks-to-buy-right-now-2020-01-23", "https://www.nasdaq.com/articles/3-top-drug-stocks-to-own-in-2020-2020-01-03", "https://www.nasdaq.com/articles/top-gainers%3A-thor-acquired-ftsv-up-on-magrolimab-data-investors-believe-fate-2019-12-09", "https://www.nasdaq.com/articles/fate-therapeutics-soars-as-much-as-45.8-after-giving-investors-what-they-wanted-2019-12-09", "https://www.nasdaq.com/articles/2-top-biotech-stocks-to-buy-in-december-2019-12-09", "https://www.nasdaq.com/articles/heres-why-fate-therapeutics-dropped-as-much-as-19.9-today-2019-11-06", "https://www.nasdaq.com/articles/heres-my-top-stock-to-buy-in-march-2020-03-06", "https://www.nasdaq.com/articles/fate-crosses-below-key-moving-average-level-2019-09-17", "https://www.nasdaq.com/articles/fate-therapeutics-inc.-fate-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/first-week-of-september-20th-options-trading-for-fate-therapeutics-fate-2019-07-26", "https://www.nasdaq.com/articles/are-natural-killer-cells-the-next-big-thing-in-immunotherapy-2019-07-08", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-xle-xbi-2019-06-06", "https://www.nasdaq.com/articles/fate-therapeutics-inc-fate-q4-2018-earnings-conference-call-transcript-2019-03-06", "https://www.nasdaq.com/articles/earnings-reaction-history-fate-therapeutc-600-follow-through-indicator-60-sensitive-2019", "https://www.nasdaq.com/articles/fate-therapeutics-inc-fate-q3-2019-earnings-call-transcript-2019-11-06", "https://www.nasdaq.com/articles/fate-crosses-below-key-moving-average-level-2019-09-17", "https://www.nasdaq.com/articles/fate-therapeutics-inc.-fate-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-rises-8.9-2018-12-03", "https://www.nasdaq.com/articles/fate-therapeutics-fate-reports-q3-loss-lags-revenue-estimates-2018-11-01", "https://www.nasdaq.com/articles/nobel-prize-cancer-immunotherapy-biotech-etfs-buy-2018-10-08", "https://www.nasdaq.com/articles/3-small-biotech-stocks-52-week-highs-are-they-buys-2018-10-03", "https://www.nasdaq.com/articles/health-care-sector-update-09182018-fate-mor-ci-navb-2018-09-18", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-5-2019-rost-coo-urbn-avav-amba-ssw-fate-regi-ags-unfi", "https://www.nasdaq.com/articles/diamond-stocks-arent-forever-your-shot-easy-358-gain-2018-04-19", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-5-2018-yy-dsgx-alog-parr-frpt-fate-nvgs-nx-pkoh-asna", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-02-24", "https://www.nasdaq.com/articles/heres-why-fate-therapeutics-rose-much-18-today-2018-01-23", "https://www.nasdaq.com/articles/tuesday-sector-leaders-gas-utilities-biotechnology-stocks-2018-01-23", "https://www.nasdaq.com/articles/3-stocks-under-10-surged-today-2018-01-18", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2017-12-30", "https://www.nasdaq.com/articles/tuesdays-etf-movers-gxc-xbi-2018-07-24", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-fate-therapeutics-fate-stock-2017-12-05", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-14-2017-sbs-holi-extr-atto-fsm-plab-hil-ast-ocx-fate", "https://www.nasdaq.com/articles/health-care-sector-update-08082017-fatefgenbioa-2017-08-08", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-15-2017-vips-aby-edit-dxpe-fsm-vray-gain-kura-fate-voxx", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-fate-therapeutics-fate-2017-03-28", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-apollo-investment-ballard-power-systems-cymabay", "https://www.nasdaq.com/articles/explosive-stocks-under-10-2017-03-07", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-rises-5.7-2017-12-28", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-fate-therapeutics-fate-stock-2017-12-05", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-14-2017-sbs-holi-extr-atto-fsm-plab-hil-ast-ocx-fate", "https://www.nasdaq.com/articles/wednesday-sector-laggards-biotechnology-drugs-2016-10-12", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-fate-therapeutics-fate-2016-09-23", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-22.8-higher-2016-08-09", "https://www.nasdaq.com/articles/health-care-sector-update-08082016-fatemeipchek-2016-08-08", "https://www.nasdaq.com/articles/fate-therapeutics-fate-shares-march-higher-can-it-continue-2017-02-22", "https://www.nasdaq.com/articles/geron-gern-q2-earnings-whats-store-stock-2016-08-01", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-rises-5.9-2016-07-29", "https://www.nasdaq.com/articles/fates-fate-protmune-gets-fast-track-status-stock-up-2016-06-21", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-jumps-19.1-2016-06-21", "https://www.nasdaq.com/articles/midday-update-wall-street-rallies-new-poll-dims-chances-brexit-2016-06-20", "https://www.nasdaq.com/articles/close-update-wall-streets-relief-rally-triggered-fading-brexit-support-2016-06-20", "https://www.nasdaq.com/articles/health-care-sector-update-06202016-fatelptnegrx-2016-06-20", "https://www.nasdaq.com/articles/arena-arna-q2-earnings-whats-store-stock-2016-08-01", "https://www.nasdaq.com/articles/geron-gern-q2-earnings-whats-store-stock-2016-08-01", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-rises-5.9-2016-07-29", "https://www.nasdaq.com/articles/vertex-vrtx-down-crl-kalydeco-label-expansion-2016-02-08", "https://www.nasdaq.com/articles/novo-nordisk-posts-in-line-q4-earnings-tops-revenues-2016-02-04", "https://www.nasdaq.com/articles/wednesday-sector-laggards-biotechnology-drugs-2016-02-03", "https://www.nasdaq.com/articles/exelixiss-cabozantinib-granted-priority-review-in-the-u.s.-2016-01-29", "https://www.nasdaq.com/articles/fate-fate-to-move-protmune-into-phase-i-ii-study-in-mid-16-2016-01-27", "https://www.nasdaq.com/articles/health-care-sector-update-05172016-fate-abeo-2016-05-17", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-6.5-higher-2016-04-11", "https://www.nasdaq.com/articles/can-fate-therapeutics-fate-keep-the-earnings-streak-alive-this-quarter-2015-12-09", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-moves-5.3-higher-2015-11-18", "https://www.nasdaq.com/articles/health-care-sector-update-10062015-cprx-infi-fate-2015-10-06", "https://www.nasdaq.com/articles/fate-therapeutics-fate-in-focus%3A-stock-rises-6.6-tale-of-the-tape-2015-07-01", "https://www.nasdaq.com/articles/juno-therapeutics-juno-q1-loss-narrower-than-expected-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-rises-46-tale-of-the-tape-2015-05-07", "https://www.nasdaq.com/articles/adaptimmune-therapeutics-adap-in-focus%3A-stock-tanks-10.5-2016-01-12", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-12.4-higher-tale-of-the-tape-2015-04-21", "https://www.nasdaq.com/articles/will-fate-therapeutics-fate-continue-to-surge-higher-tale-of-the-tape-2015-01-05", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-adds-6.4-in-session-tale-of-the-tape-2014-11-19", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-11-2014-fosl-yy-taho-hmin-lxft-stkl-aeri-mgnx-supn", "https://www.nasdaq.com/articles/fate-reports-in-line-loss-in-q4-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/fate-therapeutics-prohema-in-phase-ii-study-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/fate-therapeutics-fate-shares-march-higher-can-it-continue-tale-of-the-tape-2015-05-07", "https://www.nasdaq.com/articles/fate-therapeutics-prices-ipo-6-low-end-revised-range-2013-10-01", "https://www.nasdaq.com/articles/orphan-disease-biotech-fate-therapeutics-decreases-range-and-increases-shares-offered-2013", "https://www.nasdaq.com/articles/9-us-ipos-planned-week-sep-30-2013-09-30", "https://www.nasdaq.com/articles/13-us-ipos-planned-week-sep-23-2013-09-23", "https://www.nasdaq.com/articles/12-us-ipos-planned-week-sep-16-2013-09-16", "https://www.nasdaq.com/articles/orphan-disease-biotech-fate-therapeutics-sets-terms-60-million-ipo-2013-09-03", "https://www.nasdaq.com/articles/insiders-buy-shares-fate-therapeutics-and-chemocentryx-2013-10-08"], "Content": []}